SELEXID

Reason for request

Clinical Benefit

Substantial	Substantial only in the case of acute uncomplicated cystitis in women.
Insufficient	Insufficient for reimbursement for hospital use in view of the treatment alternatives available for other urinary tract infections: acute complicated cystitis, pyelonephritis and acute prostatitis.

Clinical Added Value

no clinical added value

Given the absence of any comparative studies versus the alternatives currently used in France in the treatment of acute uncomplicated cystitis in women, the Committee considers that the proprietary medicinal product SELEXID does not provide any improvement in actual benefit (IAB V, non-existent) in the management of acute uncomplicated cystitis in women.